Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2016 16:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 10, 2016

FORT WASHINGTON, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, May 10, 2016 at 4:30...
March 30, 2016 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Closes Public Offering of Common Stock

FORT WASHINGTON, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the completion of its underwritten public...
March 24, 2016 09:00 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Prices Public Offering of Common Stock

FORT WASHINGTON, Pa., March 24, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the pricing of an underwritten public...
March 23, 2016 16:01 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Proposes Public Offering of Common Stock

FORT WASHINGTON, Pa., March 23, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) (Vitae), a clinical-stage biotechnology company, today announced that it intends to offer and sell...
March 16, 2016 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis

VTP-43742 demonstrated statistically significant efficacy and was well tolerated Company plans to move VTP-43742 forward into 16-week study ...
March 03, 2016 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Operating and Financial Results

Proof-of-concept data for VTP-43742 expected in the first quarter of 2016 Initiated proof-of-concept trial of VTP-38543 in patients with atopic dermatitis Conference call scheduled for 4:30 p.m. EST...
February 25, 2016 16:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016

FORT WASHINGTON, Pa., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, March 3, 2016 at...
December 29, 2015 07:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Doses First Patients in Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis

FORT WASHINGTON, Pa., Dec. 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has dosed the first patients in its...
December 17, 2015 16:15 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Reports Top-Line Results From Remaining Monotherapy Arm of Phase 2 Clinical Trial of BI187004 in Overweight Type 2 Diabetes Patients

FORT WASHINGTON, Pa., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the...
December 14, 2015 16:15 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Announces Addition to the NASDAQ Biotechnology Index

FORT WASHINGTON, Pa., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has been added to the NASDAQ...